首页 > 市场调查报告书 > 製药

消化器

市场调查报告书

商品编码

1528928

外分泌胰臟功能不全治疗市场 - 按治疗（营养管理、胰酶替代疗法）、药物类型（Creon、Zenpep、Pancreaze、Ultresa、Viokace）、适应症、配销通路- 全球预测（2024 - 2032）

Exocrine Pancreatic Insufficiency Treatment Market - By Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy), Drug Type (Creon, Zenpep, Pancreaze, Ultresa, Viokace), Indication, Distribution Channel - Global Forecast (2024 - 2032)

出版日期: 2024年05月07日 | 出版商:

Global Market Insights Inc. | 英文 298 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于老年人口不断增加，外分泌胰臟功能不全治疗市场规模预计从 2024 年到 2032 年复合年增长率将达到 6.6%。最近，临床医生正在开发和完善治疗方法，以改善消化酵素的补充，以更好地吸收营养。这些治疗有助于缓解老年患者的症状，例如营养不良和胃肠道不适。

最近，正在进行的研究正在增强酶製剂和递送方法，以根据个别患者的需求量身定制个性化酶疗法，并改进诊断工具以早期检测和管理外分泌胰腺功能不全（EPI）相关併发症。《2022 年世界人口展望》强调，与较年轻的年龄层相比，65 岁及以上人口的成长率更快。这一趋势凸显了人们更加重视改善外分泌胰臟功能不全的治疗，以更好地满足老年人的健康需求。

胰臟外分泌功能不全治疗产业依治疗方法、药物类型、适应症、配销通路及地区细分。

营养管理治疗领域的市场份额将在2024年至2032年间录得可观的增长率。。专家们正在完善这些方法，将饮食调整与酵素补充剂结合起来，以提高疗效和患者福祉。此外，研究工作正在带来更具针对性的疗法和优化的治疗方案，以改善患者的治疗结果和生活品质。

就分销管道而言，预计2024年至2032年，线上药局领域的EPI治疗市场将出现显着的复合年增长率。这是由于易于获得治疗，为患者提供了一个方便的平台来订购治疗吸收不良和消化问题等症状所需的处方药和酵素补充剂。药剂师和医疗保健提供者正在积极利用这些平台来确保及时交付和患者关于治疗依从性的教育。

由于医疗基础设施的改善以及持续的药物开发和创新努力，到 2032 年，亚太地区胰臟外分泌功能不全治疗产业规模将创下显着的复合年增长率。医疗机构积极升级，以更好地诊断和管理 EPI，从而提供更多必要的药物和治疗。研究人员和製药公司正在开发新药和治疗方案，以提高疗效和患者治疗效果。药物输送系统和治疗方法的持续创新确保亚太地区的 EPI 患者获得最先进的护理，并提高该地区胰腺功能不全患者的生活品质。

产业生态系统分析
产业影响力
- 成长动力
- 慢性胰臟炎（CP）和囊性纤维化的盛行率不断增加
- 人口老化加剧
- 诊断方面的进步
- 製药业的技术进步
- 产业陷阱与挑战
- 治疗费用高
- 认识和教育有限
成长潜力分析
监管环境
技术景观
管道分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
竞争定位矩阵
战略展望矩阵

第 5 章：市场估计与预测：按处理方式，2021 - 2032 年

主要趋势
营养管理
胰酵素替代疗法（PERT）

第 6 章：市场估计与预测：按药物类型，2021 - 2032 年

主要趋势
克瑞翁
曾佩普
胰脏
乌特雷萨
维奥卡塞
其他药物类型

第 7 章：市场估计与预测：按指标划分，2021 - 2032 年

主要趋势
腹痛
便秘
腹泻
脂肪粪便
减肥
其他适应症

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

主要趋势
医院药房
零售药局
网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Abbott Laboratories
AbbVie Inc.
Allergan plc
Alexion Pharmaceuticals, Inc.
Anthera Pharmaceuticals Inc.
Amgen Inc.
AstraZeneca Plc
BioMarin Pharmaceutical Inc.
Cilian AG
Digestive Care, Inc.
Eli Lilly and Company
Johnson & Johnson
Nordmark Arzneimittel GmbH & Co. KG
Sanofi
Takeda Pharmaceutical Company Limited

简介目录

Product Code: 9379

Exocrine Pancreatic Insufficiency Treatment Market size is set to record 6.6% CAGR from 2024 to 2032 due to the rising geriatric population. Lately, clinicians are developing and refining therapies to improve digestive enzyme supplementation for better nutrient absorption. These treatments help to alleviate symptoms, such as malnutrition and gastrointestinal discomfort in elderly patients.

Lately, the ongoing research is enhancing enzyme formulations and delivery methods to personalize enzyme therapies tailored to individual patient needs as well as improved diagnostic tools for early detection and management of exocrine pancreatic insufficiency (EPI)-related complications. The World Population Prospects 2022 highlighted a faster growth rate among the population aged 65 years and older compared to younger age groups. This trend is underscoring the heightened emphasis on improving treatment for exocrine pancreatic insufficiency to better address the health needs of the elderly.

The exocrine pancreatic insufficiency treatment industry is segmented into treatment, drug type, indication, distribution channel, and region.

The market share from the nutritional management treatment segment will record a decent growth rate between 2024 and 2032. This treatment method involves tailoring diets and enzyme replacement therapies to individual patient needs to optimize nutrient absorption and alleviate symptoms like malnutrition and digestive discomfort. Specialists are refining these approaches for integrating dietary adjustments with enzyme supplements to enhance efficacy and patient well-being. Additionally, research efforts are leading to more targeted therapies with optimized treatment protocols to improve patient outcomes and quality of life.

In terms of distribution channels, the EPI treatment market from the online pharmacies segment is anticipated to witness a significant CAGR from 2024-2032. This is driven by the easy access to treatments for providing a convenient platform for patients to order prescription medications and enzyme supplements necessary for managing symptoms, such as malabsorption and digestive issues. Pharmacists and healthcare providers are actively leveraging these platforms to ensure timely delivery and patient education on treatment adherence.

Asia Pacific exocrine pancreatic insufficiency treatment industry size will record significant CAGR through 2032 due to improving healthcare infrastructure and ongoing drug development and innovation efforts. Healthcare facilities are actively upgraded to better diagnose and manage EPI for providing enhanced access to necessary medications and therapies. Researchers and pharmaceutical companies are developing new drugs and treatment protocols to improve efficacy and patient outcomes. Ongoing innovations in drug delivery systems and therapeutic approaches are ensuring that EPI patients in Asia Pacific receive state-of-the-art care with improved quality of life for individuals living with pancreatic insufficiency across the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.2 Increasing prevalence of chronic pancreatitis (CP) and cystic fibrosis
- 3.2.3 Growing aging population
- 3.2.4 Advancements in diagnosis
- 3.2.5 Technological advancements in pharmaceutical industry
- 3.2.6 Industry pitfalls & challenges
- 3.2.7 High cost of treatment
- 3.2.8 Limited awareness and education
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Nutritional management
5.3 Pancreatic enzyme replacement therapy (PERT)

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Creon
6.3 Zenpep
6.4 Pancreaze
6.5 Ultresa
6.6 Viokace
6.7 Other drug types

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Abdominal pain
7.3 Constipation
7.4 Diarrhea
7.5 Fatty stools
7.6 Weight loss
7.7 Other indications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa